An inhaled mRNA-based treatment for patients with cystic fibrosis from Translate Bio failed to produce meaningful improvements in lung function, the company said Wednesday.
The new clinical trial results, while still preliminary, are a setback for Translate’s effort to develop its first drug based on messenger RNA — the same protein-making technology powering a pair of effective Covid-19 vaccines.
Translate isn’t ready to give up on the drug, called MRT5005, just yet. Additional patients are being treated, with more data coming in the second half of the year. “We’ll make a very data-driven decision on what’s the right, next move. I don’t think we’re ready to decide, one way or the other, the future of MRT5005,” said CEO Ron Renaud.
About the Author Reprints
